author-photo

Berit Nicolaisen

10

Papers

15

Citations

Citation Trend

Filter By

Papers (9) Sort By

Journal Conference Others

Safety, anti-tumor activity and T-cell responses in a dose-ranging phase 1 trial of the oncolytic peptide LTX-315 in patients with solid tumors

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
A phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates de novo T-cell responses and clinical benefit in patients with advanced solid tumors.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
A phase I dose escalation study of intra-tumoral LTX-315 as monotherapy or in combination with either ipilimumab or pembrolizumab in patients with transdermally accessible tumors (NCT01986426)

2017
Show All
- Source
- Cite
- Save
Citations (0)
LTX-315, an oncolytic peptide, to convert immunogenically ‘cold' tumors to ‘hot' in patients with advanced or metastatic tumours: Results from an ongoing phase I study.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Abstract CT108: A phase I dose escalation study of intra-tumoral LTX-315 as monotherapy or in combination with either ipilimumab or pembrolizumab in patients with transdermally accessible tumors (NCT01986426)

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
LTX‐315, an oncolytic peptide converts "cold" tumors to "hot" in a majority of patients with advanced cancer: results from an ongoing phase I study

2017
Show All
- Source
- Cite
- Save
Citations (0)
A phase I study with LTX-315, an immunogenic cell death inducer, in patients with transdermally accessible tumors.

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Diethyl 2,5-bis-(triisopropylsilylethynyl)terephthalate

2004 Acta Crystallographica
Show All
- Source
- Cite
- Save
Citations (0)
Cleavage MapofBacteriophage T4Cytosine-Containing

1979
- Karin Carlson
- Berit Nicolaisen
Show All
- Source
- Cite
- Save
Citations (0)